NK Cell Therapy for Recurrent Brain Tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Confirmed malignant brain tumor with imaging showing it's growing or has returned after prior treatment
- Good enough overall health to tolerate the therapy (Karnofsky score ≥60%)
- Completed prior cancer treatments (like chemotherapy or radiation) at least 4 weeks before joining, with minimal lingering side effects
- Blood counts, liver function, kidney function, and heart function all within acceptable ranges
- No active infections (including HIV, hepatitis B/C) and no uncontrolled serious illness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental immune cell therapy for a type of brain tumor called malignant meningioma that has come back after standard treatment. The goal is to see if these special immune cells can help control the tumor.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This trial tests a new treatment using donated natural killer (NK) cells injected into the body to fight high-grade brain tumors. It might help people with certain types of aggressive gliomas that are newly diagnosed.
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.